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Abstract
Background: Aceltylcysteine has been evaluated in several small trials as a means of reducing the
risk of contrast-induced nephropathy (CIN), however systematic reviews of these studies do not
provide conclusive answers. Therefore, a large randomized controlled trial (RCT) is needed to
provide a reliable answer as to whether acetylcysteine is effective in decreasing the risk of CIN in
high-risk patients undergoing angiographic procedures.
Methods: ACT is a RCT of acetylcysteine versus placebo in 2,300 patients at-risk for CIN
undergoing an intravascular angiographic procedure. The randomization list will be concealed.
Participants, health care staff, investigators and outcome assessors will be blinded to whether
patients receive acetylcysteine or placebo. All analysis will follow the intention-to-treat principle.
The study drugs (acetylcysteine 1200 mg or placebo) will be administered orally twice daily for two
doses before and two doses after the procedure. The primary outcome is the occurrence of CIN,
defined as a 25% elevation of serum creatinine above baseline between 48 and 96 hours after
angiography.
Discussion: The first patient entered the trial on September, 2008. Up to April 7, 2009, 810
patients had been included in 35 centers. The mean age was 69 (Standard deviation: 10), 18% had
a baseline serum creatinine >1.5 mg/dL, 57% were diabetics and 13% had a history of heart failure.
The ongoing ACT Trial is the largest multicentre RCT that will determine whether acetylcysteine
is effective in decreasing the risk of CIN in patients at risk undergoing angiography.
Trial registration: Clinicaltrials.gov NCT00736866
Background
Contrast-induced nephropathy (CIN) is a potentially seri-
ous complication of diagnostic and therapeutic proce-
dures requiring intravenous administration of
radiocontrast media. CIN is the third most common cause
of new acute renal failure in hospitalized patients and is
associated with the need of dialysis, prolonged hospital
stay, increased health care costs and death[1,2]
The incidence of a rise in the serum creatinine of more
than 50% above baseline or of more than 1 mg/dL is neg-
ligible in patients with normal renal function[3] How-
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ever, patients with previous risk factors such as preexisting
renal failure, diabetes, congestive heart failure, advanced
age or concurrent administration of nephrotoxic drugs are
at a much increased risk. [4] The incidence of CIN has
been reported as 9 to 38% in patients with mild to mod-
erate renal insufficiency and diabetes mellitus. [3,5]
Patients requiring coronary intervention are another
group at increased risk, with an overall incidence of acute
renal failure (defined as a 25% increase in serum creati-
nine above baseline) of 14.4%. [2]
Optimal care to prevent CIN remains uncertain. [6]
Patients with normal renal function and no other risk fac-
tors are at little risk and few measures are needed except
for avoidance of volume depletion. For patients at
increased risk the most well established measures are: 1)
Avoidance of high osmolal agents[7]; 2) Avoidance of
larger radiocontrast doses and repetitive studies (less than
48 hours apart); 3) Volume expansion with isotonic flu-
ids[8] The infusion of isotonic sodium bicarbonate has
been shown to be superior to isotonic saline to prevent
CIN in most, but not all, randomized controlled trials. [9-
12]
The role of acetylcysteine in preventing CIN has been eval-
uated in several randomized controlled trials and system-
atic reviews, being the most widely studied of all
prophylaxis strategies. [13-16] Previous trials have low
statistical power (median study size was 80 patients) and
most failed to met quality standards such as allocation
concealment, blinding, and intention-to-treat analysis.
Similarly, systematic reviews and meta-analysis have
found conflicting results. The most recent review, pub-
lished by Kelly et al., included 26 randomized trials and
found a protective effect of acetylcysteine (relative risk
reduction of 38%), but with significant heterogeneity
between the included trials (I2 of 55%), meaning that
55% of the heterogeneity found could not be explained by
chance alone. [16] This quite significant heterogeneity
among studies' results prevents definitive conclusions to
be drawn. An attempt to reveal the causes of heterogeneity
using unsupervised clustering analysis revealed that a few
smaller trials of average lower quality had similar very
favorable results. [15] Removing these studies would
leave another cluster of homogeneous trials with ade-
quate quality showing neutral effect of acetylcysteine for
preventing CIN. Besides methodological quality, differ-
ences in contrast media, outcome definitions, patient
selection, dose and route of administration of acetyl-
cysteine, and co-interventions may have contributed to
the observed heterogeneity between trials.
Thus, the available evidence on the effects of acetyl-
cysteine does not allow definitive conclusions about the
efficacy of acetylcysteine for prevention of CIN. Moreover,
it is not clear from previous evidence, what is the most
effective dose of acetylcysteine, and what population ben-
efits most from this intervention. A large randomized con-
trolled trial, with high methodologic quality, involving
several centers and with sufficient power to evaluate clin-
ically relevant outcomes is needed to ultimately resolve
whether acetylcysteine prevents CIN.
The ACT Trial is a randomized controlled trial to deter-
mine whether acetylcyteine reduces the risk for CIN in
2300 at-risk patients (ie, with previous renal failure or
with other risk factors for contrast-induced nephropathy)
undergoing an intravascular angiographic procedure. CIN
is defined as an increase of 25% in serum creatinine meas-
ured between 48 to 96 hours compared to baseline. The
ACT represents the largest trial conducted so far in this
field.
Methods
Study Design
ACT is a randomized (concealed) controlled trial of ace-
tylcysteine versus placebo in patients at-risk for CIN
undergoing an intravascular angiographic procedure. Par-
ticipants, health care staff, data collectors, outcome asses-
sors, and statisticians will be blinded to whether patients
receive acetylcysteine or placebo. All analysis will follow
the intention-to-treat principle.
Eligibility
The study population is comprised of patients at increased
risk for CIN undergoing an angiographic procedure (cor-
onary or peripheral arterial diagnostic intravascular angi-
ography or percutaneous intervention). Therefore, risk
factors for CIN such as previous renal failure, diabetes
mellitus, heart failure, shock states and age greater than 70
years old were selected as the ACT study's inclusion crite-
ria. [6] The Appendix presents the ACT trial's inclusion
and exclusion criteria.
Randomization and Allocation Concealment
Patients are randomized after providing a written
informed consent in a 1:1 ratio to receive acetylcysteine or
matching placebo. The random allocation list was gener-
ated in random permuted blocks of variable size (4, 6, 8
or 10) and was stratified by investigator centre. In order to
guarantee concealment of the allocation list, randomiza-
tion is implemented through a 24-hour web-based auto-
mated randomization system, making the sequence
allocation totally unpredictable for the professionals
responsible for entering the patients in the trial in each
centre. The randomization list was generated and imple-
mented by the The ACT study Clinical Data Management
System (CDMS), a web based system that has been devel-
oped on a Microsoft SQL® platform by a team of program-
mers of the Research Institute – Hcor, Sao Paulo, Brazil.Trials 2009, 10:38 http://www.trialsjournal.com/content/10/1/38
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Interventions
Study Drugs
The study drugs (acetylcysteine 1200 mg or matching pla-
cebo) will be administered orally twice daily for two doses
before the procedure and two doses after the procedure
(Figure 1). On occasion, when the patient is included in
the study on the same day of the angiography, the prag-
matic design of the ACT trial allows one dose to be admin-
istered at least 6 hours before the procedure and three
doses after it.
Cointerventions
Hydration with 0.9% saline, 1 mL/kg/hour, starting 6–12
hours before angiography and continued for 6–12 hours
after is strongly recommended for all patients. Changes in
the total volume or flow may be needed according to
attending physician, for example, for patients with signs
of congestive heart failure.
All other decisions about management of patients are at the
discretion of the responsible doctor, except that non-trial
acetylcysteine will not be allowed during the trial period.
Blinding
All study participants will be blinded to the assigned treat-
ment, including patients, healthcare personnel, investiga-
tors and outcome assessors. The study statistician will be
the only person able to access unblinded data, albeit she
will not have any contact with participants and will not to
carry any analysis according to study group before the
database is locked.
The study drug, acetylcysteine or placebo, are packed in
identical envelops. The envelop label contains informa-
tion about the study drug and the treatment number. Each
envelop contains 600 mg of oral powder acetylcisteine or
placebo to be diluted in water. The powder and the solu-
tion in water are identical in appearance, taste and smell.
In this regard, both are orange flavored.
Outcomes
All outcomes of interest will be assessed in a blinded fashion.
Data will be obtained at baseline, 48–96 hours and 30 days.
The primary outcome of the ACT Trial is the occurrence of
contrast-induced nephropathy (CIN), defined as a 25% ele-
vation of serum creatinine above baseline between 48 and
96 hours after angiography. The secondary outcomes are: (1)
A composite outcome of death, need of dialysis or a dou-
bling in serum creatinine in thirty days; (2) A composite of
death or need of dialysis in thirty days; (3) Individual com-
ponents of the composite outcome.
Data Collection and Management
Baseline Data
The following data will be recorded at the baseline visit:
￿ Patient's initials, gender, date of birth;
Flowchart of study drug administration Figure 1
Flowchart of study drug administration. Angiography may be done at any time between 6 hours after the first study drug 
dose to just before the 3rd study drug dose.
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￿ Inclusion and exclusion criteria;
￿ Relevant medical history: hypertension; use of non-
steroidal anti-inflammatory within last 7 days; use of
angiotensin converting enzyme inhibitors, diuretics,
metformin; use of aminoglycosides, vancomycin, and
other antibiotics;
￿ Serum creatinine: The most recent serum creatinine
measured within the last three months will be
recorded. When a recent creatinine measure is not
available, a blood sample measurement will be drawn
before angiography;
￿ Physical exam: arterial blood pressure and weight;
￿ Whether the patient undergone an angiographic pro-
cedure in the last 72 hours; if yes, the purpose (diag-
nosis or treatment), and whether any measure to
prevent CIN was provided.
Treatment Data
The following data regarding treatment will be obtained:
￿ Administration of the first and second study drug
doses; with details regarding timing and amount per
dose;
￿ Hydration scheme before angiographic procedure:
type of solution, total volume and duration of infu-
sion;
￿ Angiographic procedure: date, hour and type (coro-
nary or peripheral; diagnostic or therapeutic; if thera-
peutic, angioplasty, bare metal stent, drug-eluted stent
or a combination of them;
￿ Contrast: type, volume administered;
￿ Whether the procedure was indicated for a patient
with acute coronary syndrome.
Short-Term Follow-up Data
This is the main follow-up visit. Patients will have a serum
creatinine measured between 48 and 96 hours after angi-
ography for evaluation of the study primary outcome.
Other data elements which will be recorded are:
￿ Administration of the third and fourth study drug
doses; with details regarding timing and amount per
dose;
￿ Hydration scheme after angiographic procedure: type
of solution, total volume and duration of infusion;
￿ Whether the patient undergone an angiographic pro-
cedure within 72 hours after the index angiography; if
yes, date, type, and measures to prevent CIN;
￿ Vital status; in case of deaths, date and cause;
￿ Need of dialysis.
One month follow-up data
Research personnel will contact patients 30 days after the
angiographic procedure and record the occurrence of:
￿ Angiographic procedure: date, type, measures to pre-
vent CIN;
￿ Vital status; in case of deaths, date and cause;
￿ Need of dialysis.
Adverse events form
This form contains questions for adverse events which
may occasionally occur after acetylcysteine (nausea, eme-
sis, urticaria, bronchospasm), open questions for registra-
tion of any other adverse event, and a question for severe
adverse event with a field for detailing the event.
Clinical Data Management System (CDMS) and Quality Control
The ACT study CDMS is a web based system that has been
developed on a Microsoft SQL® platform by a team of pro-
grammers of the Research Institute – HCor. Its functional-
ities include: patient registration, 24-hour concealed
randomization, data entry, data cleaning and exportation
for analysis.
The CDMS also provides reports on the status of the study
forms (completed forms, overdue forms), weekly study
recruitment by center and graphs of observed and
expected cumulative recruitment.
Sample size
Based on a recent systematic review and meta-analysis of
26 randomized controlled trials, we anticipate an inci-
dence of CIN at 48 to 96 hours of approximately 15%[16]
In order to detect a 30% relative risk reduction (RRR),
with 90% statistical power, and a two-tailed alpha of 5%,
we will need to include at least 2,300 patients.
Statistical Analysis Plan
All analysis will follow the intention-to-treat principle.
The effect of acetylcysteine versus placebo on the primary
endpoint, incidence of CIN between 48 to 96 hours, will
be evaluated with a chi-square test. The magnitude of
association will be presented as a risk ratio, with 95% con-
fidence interval and number needed to treat (NNT). Sta-Trials 2009, 10:38 http://www.trialsjournal.com/content/10/1/38
Page 5 of 8
(page number not for citation purposes)
tistical significance will be inferred using a significance
level of 0.05.
Secondary outcomes evaluated 30 days after randomiza-
tion will be presented as Kaplan-Meier curves according to
the assigned treatment, and tested with the log-rank
method. Hazard ratios and 95% confidence intervals will
be calculated using non-adjusted Cox proportional haz-
ards.
The incidence of the primary outcome will be analyzed in
pre-specified subgroups using risk ratios and 95% confi-
dence intervals. A subgroup effect will be inferred when
the chi-squared test for homogeneity of effects is statisti-
cally significant. The following subgroups will be ana-
lyzed: 1) ≤70 year-old versus >70 year-old; 2) Male vs.
female; 3) No previous renal failure vs. previous renal fail-
ure (serum creatinine >1.5 mg/dL); 4) Not diabetic vs dia-
betic; 5) Amount of contrast agent <140 mL vs. ≥140 mL.
[17]
In the main trial publication, we also plan to include a
random effects (DerSimonian-Laird) meta-analysis to
combine ACT's results with those of previous randomized
controlled trials evaluating acetylcysteine versus placebo
for prevention of contrast-induced nephropathy. [18]
Ethical Aspects
Each study site will submit the study protocol to its insti-
tutional Research Ethics Board (REB). The study should
start only after being approved by the REB. Written
informed consent will be obtained from all participants.
This study is in compliance with the Helsinki Declaration.
Trial Organization and Management
Trial Management Team (TMT)
A team based on the Research Institute -Hcor, São Paulo,
Brazil, will manage the trial on a day-to-day basis. The
TMT is comprised by the chief investigator, a project man-
ager, a clinical research associate, a statistician and four
computer programmers. Data management is assumed by
both the medical project manager and the clinical
research associate.
The responsibilities of the TMT include:
- Selecting and training participant centers;
- Assisting trial centers with regulatory submissions;
- Distributing and supplying study sites with the study
drug and forms;
- Monitoring recruitment and follow-up at participant
centers;
- Data management: Elaboration, testing and mainte-
nance of the electronic data capture system; data qual-
ity control;
- Data analysis;
- Servicing the Trial Steering Committee.
Trial Steering Committee (TSC)
The TSC is responsible for providing overall supervision
of the trial, assist with development of the study protocol
and preparing the final manuscript. All other trial's com-
mittees report to the TSC. The TSC members are epidemi-
ologists, with in-dept training in designing and
conducting randomized controlled trials, or cardiologists
experienced in the conduction of multicentre clinical tri-
als.
Trial Centers
Fifty four invasive catheterization centers in Brazil are par-
ticipating in the study. Details of the participating centers
are given in the Appendix.
Publication policy
The ACT study success depends on all its collaborators.
Therefore, the primary results of the trial will be published
under the name of ACT Trial Investigators. The contributions
of all collaborators, their names and respective institutions,
not only the members from TSC or TMT, will be acknowl-
edged in the manuscript. To safeguard the scientific integrity
of the study, data from this study will be submitted to publi-
cation only after the final approval from the TSC.
Data Monitoring Committee
The ACT Study does not have a Data Monitoring Commit-
tee, nor will we conduct interim analysis to evaluate drug
Table 1: Baseline demographic and clinical characteristics
Characteristic Total
(N = 810)
Female sex – no. (%) 305 (38)
Age – years
Mean (SD) 69 (10)
Patients fulfilling inclusion criteria – no. (%)
Recent creatinine >1.5 mg/dL 148 (18)
Diabetes mellitus 458 (57)
Heart failure 105 (13)
Shock 2 (0.2)
Aged >70 years 458 (57)
History of hypertension – no. (%) 659 (81.4)
Serum creatinine – mg/dL
Median (IQR) 1.1 (0.5)
Estimated creatinine clearance* – mL/kg/min
Median (IQR) 60 (38)
SD, standard deviation; IQR, interquartile range.
* Creatinine clearance estimated by the Cockcroft-Gault formula.Trials 2009, 10:38 http://www.trialsjournal.com/content/10/1/38
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efficacy or safety. The arguments supporting this decision
are: 1) Oral acetylcysteine has a very good safety profile,
being tested in several small clinical trials and used in
practice for a long period of time. Adverse reactions (spe-
cially unexpected severe adverse events) and drug interac-
tions are uncommon and rarely severe. [19] Therefore,
early stopping for safety reasons would be highly unlikely.
2) Trials stopped early for benefit usually reach large and
non-plausible treatment effects (relative risk reductions
greater than 50%) due to low numbers of events and thus
low statistical power to reach robust results. In conse-
quence, several experts in the field of clinical trials have
criticized and discouraged such an approach. [20] 3) The
study has limited power to evaluate clinical events such as
need of dialysis or death. We expect an incidence of need
of dialysis or death in 30 days between 2% and 3%. A
study enrolling 7,650 patients would be needed to have
80% power to show a reduction in this combined out-
come from 3% to 2%. Therefore, it is very unlikely that
evidence of benefit beyond doubt on clinical outcomes
would be found in an interim analysis.
Discussion
Contrast-induced nephropathy is a common complica-
tion after coronary or peripheral angiography. Patients at
increased risk include those with previous renal failure,
diabetes mellitus, heart failure, shock states and elderly.
[4] Acetylcystine represents a simple, non-toxic, low-cost,
and wide available intervention. The majority of previous
trials that tested this intervention had small sample sizes,
inadequate methodology, have reached conflicting
results, and have not assessed patient-important out-
comes. At present there is limited evidence that acetyl-
cysteine together with hydration may be useful as
standard prophylactic procedure in patients at high risk
for CIN. Therefore, a well designed trial with adequate sta-
tistical power is needed to resolve the question of acetyl-
cysteine for the prevention of CIN.
ACT investigators started recruitment on September, 15,
2008. To date (April 7, 2009), 35 centers started recruit-
ment and 810 patients have been randomized. Thus, ACT
is already the largest randomized controlled trial evaluat-
ing a strategy to prevent CIN[16] Patients' baseline char-
acteristics are depicted in table 1. Mean age was 69
(standard deviation 10), with 57% being older than 70
years. Prevalence of renal failure (as defined by a baseline
serum creatinine > 1.5 mg/dL) was 18%, of diabetes was
57% and of heart failure was 13%.
The ACT study was planned to be the largest, double-
blind, randomized controlled trial, comparing acetyl-
cysteine to placebo in high risk patients undergoing
peripheral or cardiac invasive angiography conducted to
date. The results of ACT will convey a reliable and precise
estimate of acetylcysteine's effectiveness on preventing
CIN in such population. Regardless of the results, the ACT
trial will have important implications for clinical practice.
If the ACT trial demonstrates no effect on contrast induced
nephropathy and on other patient-important outcomes,
then it will allow physicians to avoid unnecessary patient
risk and decrease costs. On the other hand, if the ACT Trial
demonstrates a beneficial effect of acetylcysteine, then it
will have clinical impact on preventing renal adverse
events in high risk patients undergoing angiographic pro-
cedures.
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Appendix
Eligibility criteria of the ACT Trial
Inclusion criteria
Patients undergoing an angiographic procedure must
meet at least one of the following criteria to be included:
￿ Age > 70 years;
￿ Renal failure (defined as a serum creatinine higher
than 1.5 mg/dL within the last 3 months);
￿ Diabetes mellitus;
￿ Congestive heart failure or left ventricular ejection
fraction <0.45;
￿ Shock;
￿ Intra-aortic balloon counterpulsation.
Exclusion criteria
Patients are excluded if they met any of the following cri-
teria:
￿ Pregnant or breastfeeding women, or aged below 45
years and with no efficacious contraceptive method;
￿ Patients on dialysis;
￿ Previous enrollment in ACT study;
￿ Patient did not provide informed consent;Trials 2009, 10:38 http://www.trialsjournal.com/content/10/1/38
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￿ Patients with ST segment elevation myocardial inf-
arction unable to receive the study hydration protocol.
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